
Photo taken from Luca Malorni/LinkedIn
Jul 23, 2024, 11:27
Luca Malorni: Our editorial discussing the results of the SERENA-1 trial
Luca Malorni, Director of the Translational Research Unit at AUSL Toscana Centre at Hospital of Prato, shared on X:
“Here’s our editorial in Annals of Oncology discussing the results of the SERENA-1 trial where we share some open questions, including the issue of patients selection for these new endocrine agents.”
Source: Luca Malorni/X
The new oral SERDs in endocrine-resistant breast cancer: who will benefit the most?
Authors: I. Migliaccio, L. Biganzoli, and L. Malorni.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 11:28
Feb 22, 2025, 11:22
Feb 22, 2025, 11:15
Feb 22, 2025, 11:02
Feb 22, 2025, 10:47
Feb 22, 2025, 05:18